Sanofi and GSK Report Results of COVID-19 Vaccine in the P-III (VAT08) Trial Against Omicron
Shots:
- The P-III (VAT08) trial evaluated an adjuvanted bivalent D614 & Beta (B.1.351) vaccine in 13,000+ patients aged ≥18yrs. with COVID-19
- The results from stage 2 of the P-III trial showed a 64.7% efficacy against symptomatic COVID-19 and 75.1% in seropositive patients previously infected with COVID-19. In Omicron-confirmed symptomatic cases, 72% efficacy in all adults & 93.2% in seropositive. Stage 1 & 2 of (the VAT08) trial from ~23,000 patients showed a favorable safety & tolerability profile
- GSK plans to discuss with regulatory authorities to make available vaccine candidates in 2022. Sanofi-GSK’s beta-based booster vaccine has the potential to be a relevant solution to public health demands
Ref: GSK | Image: GSK
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
